Long-term outcomes of lobectomy vs.sublobectomy for stage I lung invasive mucinous adenocarcinoma  

作　　者：Lide Wang Guochao Zhang Chao Zheng Long Zhang Jia Jia Liyan Xue Shugeng Gao Yushun Gao Fengwei Tan Qi Xue 

机构地区：[1]Department of Thoracic Surgery,National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital,Chinese Academy of Medical Sciences and Peking Union Medical College,Beijing 100021,China [2]Department of Pathology,National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital,Chinese Academy of Medical Sciences and Peking Union Medical College,Beijing 100021,China

出　　处：《Chinese Medical Journal》2024年第15期1879-1881,共3页中华医学杂志（英文版）

基　　金：supported by the National Key R&D Program of China(No.2022YFC2407404);National High-Level Hospital Clinical Research Funding(Nos.2022-PUMCH-A-018 and 2022-PUMCH-C-043);Special Research Fund for Central Universities,Peking Union Medical College(No.2022-I2M-C&T-B-060);Beijing Hope Run Special Fund of Cancer Foundation of China(No.LC2021L01);the Beijing Municipal Science&Technology Commission(No.Z211100002921058).

摘　　要：To the Editor:Lung invasive mucinous adenocarcinoma(LIMA)is regarded as a subtype of invasive lung adenocarcinoma(LUAD).No significant differences exist in the overall survival(OS)or recurrence-free survival(RFS)between lobectomy and sublobectomy in clinical stage IA non small cell lung cancer(NSCLC)≤2 cm.[1]Besides,the studies on surgical methods in early LIMA are limited.In this study,we reviewed the clinicopathological features of LIMA and compared its prognosis under different surgical methods.

关 键 词：ADENOCARCINOMA LUNG INVASIVE 

分 类 号：R734.2[医药卫生—肿瘤]